Five antiangiogenic drugs are recommended as initial treatment of metastatic renal cell carcinoma patients.
Sunitinib, pazopanib, axitinib and bevacizumab + interferon alpha-2a yield a similar survival benefit but have different safety profiles.
These results may provide guidance to optimize treatment choices.